Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
CHICAGO -On Thursday, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) reported better-than-expected fourth quarter results and provided upbeat guidance for 2025.
The company’s shares gained 2.65% in premarket trading after the release.
The biopharmaceutical company posted Q4 adjusted earnings per share of -$0.03, beating analyst estimates of -$0.06. Revenue came in at $60.1 million, surpassing expectations of $56 million and growing 35% YoY.
For the full year 2024, Xeris achieved record revenue of $203 million, up 24% compared to 2023. The company’s Recorlev product saw particularly strong growth, with revenue more than doubling versus the prior year.
Looking ahead, Xeris provided 2025 revenue guidance of $255-275 million, above the consensus estimate of $239.8 million. At the midpoint, this represents over 30% growth compared to 2024.
"The Xeris team executed an exceptional 2024 with record revenue topping $203 million," said CEO John Shannon. "The continued momentum of our commercial business, our exciting pipeline, along with our unrelenting focus on execution will enable Xeris to create even more value for patients and shareholders."
The company ended Q4 with over $71 million in cash, generating $2 million in cash during the quarter. Management expects adjusted EBITDA to remain positive going forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.